Literature DB >> 11446706

Diagnosis of myocardial ischemia in hypertensive patients.

E Picano1, A Pálinkás, R Amyot.   

Abstract

Arterial hypertension can provoke a reduction in coronary flow reserve through several mechanisms that are not mutually exclusive (i.e. epicardial coronary artery disease (CAD), left ventricular hypertrophy and structural and/or functional microvascular disease). These different targets of arterial hypertension should be explored with different diagnostic markers. In fact, stress-induced wall motion abnormalities are highly specific for angiographically assessed epicardial CAD, whereas ST segment depression and/or myocardial perfusion abnormalities are frequently found with angiographically normal coronary arteries associated with left ventricular hypertrophy and/or microvascular disease. Exercise-electrocardiography stress test can be used to screen patients with negative maximal test due to its excellent negative predictive value, which is high and comparable in normotensives and hypertensives. When exercise-electrocardiography stress test is positive (or uninterpretable or ambiguous), an imaging stress-echo test is warranted for a reliable identification of significant, prognostically malignant epicardial CAD in view of an ischemia-guided revascularization.

Entities:  

Mesh:

Year:  2001        PMID: 11446706     DOI: 10.1097/00004872-200107000-00001

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  13 in total

Review 1.  Gene silencing in DNA damage repair.

Authors:  H Soejima; K Joh; T Mukai
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

2.  Stress echocardiography: the long and winding road from meta-analysis to bedside.

Authors:  Eugenio Picano
Journal:  Int J Cardiovasc Imaging       Date:  2005 Apr-Jun       Impact factor: 2.357

3.  Myocardial perfusion scintigraphy and echocardiography for detecting coronary artery disease in hypertensive patients: a meta-analysis.

Authors:  Paola Gargiulo; Mario Petretta; Dario Bruzzese; Alberto Cuocolo; Maria Prastaro; Carmen D'Amore; Enrico Vassallo; Gianluigi Savarese; Caterina Marciano; Stefania Paolillo; Pasquale Perrone Filardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

4.  [New ESH/ESC guidelines on arterial hypertension : what is new and what indications remain for renal denervation?].

Authors:  P Groha; S Kufner; I Ott; H Schunkert
Journal:  Herz       Date:  2014-12       Impact factor: 1.443

Review 5.  Imaging in hypertensive heart disease.

Authors:  Rajesh Janardhanan; Christopher M Kramer
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-02

6.  [Management of arterial hypertension].

Authors:  P Groha; H Schunkert
Journal:  Herz       Date:  2015-09       Impact factor: 1.443

7.  Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography.

Authors:  Jong-Won Ha; Hyun-Chul Lee; Eun-Seok Kang; Chul-Min Ahn; Jin-Mi Kim; Jeong-Ah Ahn; Se-Wha Lee; Eui-Young Choi; Se-Joong Rim; Jae K Oh; Namsik Chung
Journal:  Heart       Date:  2007-04-20       Impact factor: 5.994

Review 8.  The non-invasive documentation of coronary microcirculation impairment: role of transthoracic echocardiography.

Authors:  Pawel Petkow Dimitrow; Maurizio Galderisi; Fausto Rigo
Journal:  Cardiovasc Ultrasound       Date:  2005-08-04       Impact factor: 2.062

Review 9.  Coronary flow reserve in stress-echo lab. From pathophysiologic toy to diagnostic tool.

Authors:  Fausto Rigo
Journal:  Cardiovasc Ultrasound       Date:  2005-03-25       Impact factor: 2.062

Review 10.  The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease.

Authors:  Sophie Mavrogeni; Vasiliki Katsi; Vasiliki Vartela; Michel Noutsias; George Markousis-Mavrogenis; Genovefa Kolovou; Athanasios Manolis
Journal:  BMC Cardiovasc Disord       Date:  2017-05-23       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.